OSCRHealthcare · Healthcare PlansThe 11 Wall Street analysts covering Oscar Health, Inc. hold a median 12-month price target of $34 — +16.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 23 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Oscar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OSCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.0% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Sept 2026 | Raymond James | Maintains | Outperform | $34 → $42 |
| 17 Sept 2026 | B of A Securities | Maintains | Underperform | $28 → $30 |
| 17 Sept 2026 | Baird | Maintains | Neutral | $27 → $33 |
| 17 Sept 2026 | Barclays | Maintains | Overweight | $39 → $49 |
| 17 Sept 2026 | Stephens & Co. | Reiterates | Equal-Weight | $34 |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $20 → $27 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $35 → $39 |
| 7 Aug 2026 | UBS | Maintains | Neutral | $20 → $26 |
| 7 Aug 2026 | UBS | Maintains | Neutral | — |
| 10 June 2026 | Barclays | Upgrade | Overweight | — |
| 10 June 2026 | Barclays | Upgrade | Overweight | $30 → $35 |
| 26 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | Baird | Maintains | Neutral | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | UBS | Maintains | Neutral | — |
| 6 May 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 20 Apr 2026 | Jefferies | Upgrade | Hold | — |
| 9 Jan 2026 | UBS | Upgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSCR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Sept 2026, Oscar Health, Inc. returned +56.6% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 79% of US stocks
Cheaper than 23% of US stocks
Cheaper than 56% of US stocks
Higher than 90% of US stocks
Higher than 80% of US stocks
Higher than 60% of US stocks
Higher than 56% of US stocks
Higher than 89% of US stocks
Higher than 73% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oscar Health, Inc. has a market value of $9.7B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $15.3B. The latest quarter grew 70.4% year on year.
Net income over the same four quarters: $550.9M, a 3.6% net margin.
Diluted earnings per share, trailing twelve months: $1.40.
Free cash flow in the twelve months to 30 June 2026: $4.4B.
Trailing P/E: 23.0×; forward P/E: 13.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Oscar Health, Inc. employs 2,305 people — $6.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oscar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks reports that Oscar Health's profit rebound is facing a test as rising medical spending and a larger member base threaten its second-half profitability.
Why it matters — OSCR watchers would care because the sustainability of the insurer's earnings recovery depends on managing increased medical costs and a growing membership.
Oscar Health (OSCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could drive the stock higher in the near term, according to Zacks Investment Research.
Why it matters — A Strong Buy rating from Zacks signals improved expectations for Oscar Health's earnings, which OSCR watchers would track as a gauge of analyst sentiment.
On September 23rd, 2026, Oscar Health (OSCR) was included in Zacks Investment Research's Zacks Rank #1 (Strong Buy) momentum stocks list, alongside SNDR and TFII.
Why it matters — This signals that Zacks Research places OSCR among its top-ranked momentum stocks as of that date, which OSCR watchers may view as a notable market recognition.
Oscar Health held an Investor Day and was upgraded to Strong Buy with a new $45 fair value, reflecting raised 2026–2029 earnings targets. Management projects 2029 EPS above $4 and 2026 operating earnings of $600–800M, driven by ACA execution, CHOICE, and Lucie marketplace growth, which expand the company's addressable market by 65%, with revenue estimates rising from $18.85B in 2026 to $32.6B in 2029.
Why it matters — OSCR watchers would care because the Investor Day introduced a significantly expanded total addressable market and higher long-term earnings and revenue projections, pointing to accelerated growth driven by CHOICE and Lucie.
Oscar Health (OSCR) was added to Zacks Investment Research's Rank #1 (Strong Buy) growth stocks list on September 23rd, 2026, alongside LCUT and FIVE.
Why it matters — OSCR watchers may note that the company was recognized by Zacks as one of its top growth stocks carrying a Strong Buy ranking.
The 11 Wall Street analysts covering Oscar Health, Inc. have a median 12-month price target of $34, with estimates ranging from $26 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Oscar Health, Inc., 3 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Oscar Health, Inc. 89 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, Oscar Health, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +16.0% from the last close, and Ticker Nerd's factor model ranks Oscar Health, Inc. 89 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Oscar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $49 over the next 12 months.
Oscar Health, Inc. returned +56.6% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States.
The most recent item we track (Zacks Investment Research, 23 Sept 2026): "Can Oscar Health Sustain Its Profit Rebound as Medical Costs Rise?". Zacks reports that Oscar Health's profit rebound is facing a test as rising medical spending and a larger member base threaten its second-half profitability.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States. Oscar Health combines insurance coverage with a technology platform designed to help members access care, manage plans, and navigate the healthcare system. Its current offerings include individual and family health plans, small group coverage, and Medicare Advantage plans, along with technology solutions for providers and payors. The company operates in the managed health care and health services space, where it serves consumers and business customers through a data-driven, consumer-oriented model. Headquartered in New York, Oscar Health is positioned as a modern health insurer that integrates software, service, and clinical support across its insurance operations.
CEO Mr. Mark Thomas Bertolini · 2,305 employees · United States · https://www.hioscar.com
